Seeking Alpha·3d ago
Apyx Medical Corporation (APYX) Q3 2026 Earnings Call TranscriptApyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
APYX revenue rose 22.1% year over year to $13.9M in 2026Q2, and gross margin recovered to 63.9% from 37.4% the prior quarter, suggesting some operating traction.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.04+57.1% vs -$0.09 | $14M+5.6% vs $13M |
Q3 2026 Aug 6, 2026 | -$0.07+14.6% vs -$0.08 | $14M+5.4% vs $13M |
Q2 2026 May 7, 2026 | -$0.05+54.5% vs -$0.11 | $12M+18.7% vs $11M |
Q2 2026 Mar 10, 2026 | -$0.03+50.0% vs -$0.06 | $19M+3.4% vs $19M |
Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
Apyx Medical (APYX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago.
Apyx Medical NASDAQ: APYX reported a 9% increase in third-quarter 2026 revenue, driven by sales of its AYON body contouring system in the United States and international demand for Renuvion. The company also narrowed its full-year operating expense target while reaffirming its revenue outlook.
Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpiece for the AYON system in the third quarter Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla.
Benchmark APYX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Apyx Medical Corporation (APYX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.93 | $123.38M | -15.50 | 9.86% | -14.16% | -68.79% | — | |
| $0.00 | $589 | -0.00 | -8.54% | -21.13% | -360.33% | — | |
| $0.11 | $13.09M | -0.88 | -12.34% | -4.41% | -36.6% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $12.37 | $154.54M | -52.77 | 14.52% | -7.12% | -74.71% | — | |
| $13.33 | $766.22M | 10.21 | -6.16% | 20.69% | 11.8% | — |
Apyx Medical Corporation (APYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Apyx Medical Corporation (APYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
Aug 6, 2026·SEC
Jul 24, 2026·SEC
Get notified when APYX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Apyx Medical Corporation (APYX) stock FAQ — growth, dividends, profitability & financials explained
Apyx Medical Corporation (APYX) reported $59.6M in revenue over the trailing twelve months. Revenue was $52.8M in fiscal year 2025. That is 606% more than the $7.5M of fiscal year 1996.
Apyx Medical Corporation (APYX) grew revenue by 24.4% over the trailing twelve months, compared with the twelve months before.
No. Apyx Medical Corporation (APYX) reported a net loss of $8.4M over the trailing twelve months.
Apyx Medical Corporation (APYX) had a return on equity (ROE) of -68.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Apyx Medical Corporation (APYX) had negative free cash flow of $8.9M over the trailing twelve months.
